StemCell Therapy

HAIFA, Israel, March 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced that the Israeli Ministry of Health has approved Pluristems request to seek approvals to treat COVID-19 coronavirus patients under the per-patient compassionate use framework in Israel. The Israeli Ministry of Health may approve proposed treatments on a per-patient basis for the use of PLX cell therapy including intra-muscular (IM) administration of PLX-PAD for the proposed treatment of severe pneumonia resulting from COVID-19 and preventing the deterioration of patients towards Acute Respiratory Distress Syndrome (ARDS) and sepsis. Pluristem has not yet submitted any such request for treatment of a specific COVID-19 patient, and there is no assurance that any such request will be approved by Israeli Ministry of Health.

Pluristem recently announced a collaborative agreement with the BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT) at Charit University of Medicine Berlin to evaluate the therapeutic effects of PLX cell product candidates for the potential treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus.

Pluristem is highly committed to use its technology, knowledge and expertise in order to attempt to provide a better outcome to patients infected by complications associated with COVID-19. We hope and believe that the ease of use of our PLX cell product candidates, and their being readily available, may play an important role in case there is a need to treat large numbers of patients with respiratory complications. Our collaborative research with Charit of Berlin on our PLX COVID-19 program enables us to accelerate the implementation of our cell therapies candidates towards this indication, as we continue our efforts to expand the program to additional countries, stated Pluristem President and CEO Yaky Yanay.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large scale quantities, offering a key advantage in addressing a global pandemic. PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties that induce the immune systems natural regulatory T cells and M2 macrophages, and thus may prevent or reverse the dangerous overactivation of the immune system. Accordingly, PLX cells may potentially reduce the incidence andor severity of COVID-19 pneumonia and pneumonitis leading hopefully to a better prognosis for the patients. Previous pre-clinical findings of PLX cells revealed therapeutic benefit in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury which are potential complications of the severe COVID-19 infection. Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells in patients post major surgery. Taken together, PLX cells potential capabilities with the safety profile observed from clinical trials involving hundreds of patients worldwide potentially position them as a therapy for mitigating the tissue-damaging effects of COVID-19.

About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.

Safe Harbor Statement

This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses the potential use of its PLX cell product candidates for the proposed treatment of severe pneumonia resulting from COVID-19 and preventing the deterioration of patients towards ARDS, sepsis and death, its commitment to use its technology, knowledge and expertise in order to attempt to provide a better outcome to patients afflicted by complications associated with COVID-19, its hope and belief that the ease of use of its PLX cell product candidates and their being readily available, may play an important role in case there is a need to treat large numbers of patients with respiratory complications, that its collaborative research with Charit of Berlin on the PLX COVID-19 program enables Pluristem to accelerate the implementation of its cell therapies candidates towards this indication, its intention to continue efforts to expand its PLX COVID-19 program to additional countries, the belief that PLX cells being available off-the-shelf and can be manufactured in large scale quantities, may offer a potential key advantage in addressing a global pandemic and the belief that PLX cells may potentially reduce the incidence andor severity of COVID-19 induced pneumonia and pneumonitis. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Story continues

Originally posted here:
Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristems PLX Cells - Yahoo...

The market is estimated to grow with a CAGR of 13. 5% from 2020-2027. The growth in North America is characterized by an increase in the demand for innovative products from biopharmaceutical and biotechnology companies, the presence of key market players, and extensive R&D conducted by various academic and research institutes.

New York, March 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "North America Cell Line Development Market to 2027 - Regional Analysis and Forecasts by Type ; By Product ; Application ; and Geography" - https://www.reportlinker.com/p05875892/?utm_source=GNW Moreover, increasing focus on advanced method incorporation in healthcare, government, and private initiatives for promotion of precision medicine and massive funds from government and private bodies for genomic research are further expected to stimulate growth and contribute to exceptional revenue generation for the cell line development market in North America.

The medical biotechnology has undergone revolutions as a result of various development programs, business strategies that helps to produce, discover, or alter various biomolecules and organisms through bioengineering approaches. The Biotech Startup Revolution has also assisted in promoting the new ventures holding promising and innovative ideas in the country and supported in maximizing the revenue generation and thus the economic position of North America in the global cell line development market.Moreover, the companies are performing various activities for the cell line development market, for instance, Selexis, Carestream Avacta, JSR Life Sciences has done recent developments for products.In 2019, the recombinant cell line segment held the most significant market share of the cell line development market, by type.This segment is also anticipated to dominate the market in 2027 owing to its popularity among manufacturers for the production of therapeutic recombinant proteins.

The hybridomas segment is anticipated to witness growth at a significant rate during the forecast period.The US cell line development market is dominated by intraoral media and reagent segment in 2019 with a considerable market share, by product.This segment is also predicted to dominate the market in 2027.

Also, media and reagent segment is anticipated to witness growth at a significant rate during the forecast period, 2020 to 2027, owing to the increasing research activities in biotechnology sector.In 2019, the bioproduction segment held a considerable market share of the cell line development market, by the application.This segment is also predicted to dominate the market in 2027 owing to higher demand of biologics.

However, the drug discovery segment is anticipated to witness growth at a significant rate during the forecast period.Some of the major primary and secondary sources for cell line development included in the report are American Society of Clinical Oncology, American Type Culture Collection, California Institute for Regenerative Medicine, and others.Read the full report: https://www.reportlinker.com/p05875892/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Visit link:
The North America cell line development market is expected to reach US$ 3,829.46 Mn in 2027 from US$ 1,393.32 Mn in 2018 - Yahoo Finance

ROCKVILLE, Md., March 18, 2020 /PRNewswire/ --Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.

In July 2019, Cellphire successfully completed a Phase I clinical trial of its lead product, Thrombosomes, a platelet-based freeze-dried hemostatic. Utilizing its patented technology to stabilize and freeze-dry platelets, Cellphire is developing next-generation therapeutics to treat bleeding patients. Standard liquid platelets only have a 5- to 7-day shelf life, making inventory management difficult and can lead to widespread platelet shortages during public health emergencies. By contrast, Thrombosomes have a 3-year shelf life.

The objective of the multicenter Phase 2 study is to evaluate the safety and efficacy of infusing multiple doses of Thrombosomes in bleeding patients with thrombocytopenia due to primary bone marrow disorders or chemotherapy, immunotherapy radiation therapy, and/or refractory response to fresh platelet concentrate transfusion with or without splenomegaly (enlarged spleen).

"We are very excited to have FDA approval of our Phase 2 clinical trial," said G. Michael Fitzpatrick, Ph.D., Cellphire's President. "Thrombosomes have the potential to increase the availability of a platelet-based hemostatic product throughout the United States, especially when standard liquid platelets are not available. The product's 3-year shelf life and ease of storage could allow for stockpiling, which supports national preparedness for times of potential shortages."

The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.

About Cellphire

Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes, a freeze-dried hemostatic derived from human platelets. Cellphire's technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit http://www.cellphire.com.

View original content:http://www.prnewswire.com/news-releases/cellphire-begins-phase-2-trial-of-thrombosomes-in-bleeding-thrombocytopenic-patients-301026462.html

SOURCE Cellphire Inc.

Follow this link:
Cellphire Begins Phase 2 Trial of Thrombosomes in Bleeding Thrombocytopenic Patients - Benzinga

New Jersey, United States: A qualitative research study accomplished by Verified Market Research titled 2020-2026 Global and Regional Regenerative Medicine Market: Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report is the most up to date report which comprises the latest trends that influence the market competition in the forecast period from 2020 to 2026. The report presents different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. Primarily, the report introduces market demands and the present position of the Regenerative Medicine market.The report completes the value chain and downstream and upstream essentials.

Global Regenerative Medicine Market was valued at USD 19.10 Billion in 2018 and is expected to witness a growth of 22.72% from 2019-2026 and reach USD 98.10 Billion by 2026.

Our expert analyst has categorized the market into product type, application/end-user, and geography. All the segments are analyzed based on their market share, growth rate, and growth potential. The growth potential, market share, size, and prospects of each segment and sub-segment are portrayed in the report. This thorough evaluation of the segments would help the players to focus on revenue-generating areas of the Regenerative Medicine Market.

A number of leading manufacturers mention in the Regenerative Medicine Market research report are focusing on expanding operations in regions, as they exhibit potential business opportunities. The Regenerative Medicine Market report classifies the market dynamics and trends in the global and regional market considering several aspects including technology, supplies, capacity, production, profit, and price.

Regenerative Medicine Market: Research Methodology

1. Primary Research:

2. Secondary Research:

During our Secondary research, we collect information from different sources such as databases, regulatory bodies, gold and silver-standard websites, articles by recognized authors, certified publications, white papers, investor presentations and press releases of companies, and annual reports.

Data collection module is used for data collection and analysis of the base year. The market data is analyzed and estimated using statistical models and systematic market. The main research methodology used for the preparation of reports, including data mining, primary (industry experts) validation and top-down analysis, market overview and guidance, the company market share analysis, measurement standards, and analysis of the stock sellers.

Vendor Competitive Analysis:

The report focuses on the strategies considered by the market participants to gain a major share in the Regenerative Medicine market. Through this, the competitors will get an overview of the competitive landscape so they can make business decisions. Leading players working in the global market are analyzed with their company information, product profile, product specification, picture, capacity, production, price, cost, global investment plans, and supply-demand scenarios.

Regenerative Medicine Market Regional Coverage

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Ask For Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=PN24&utm_medium=002

Table of Content

1 Introduction of Regenerative Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Regenerative Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Regenerative Medicine Market, By Deployment Model

5.1 Overview

6 Regenerative Medicine Market, By Solution6.1 Overview

7 Regenerative Medicine Market, By Vertical

7.1 Overview

8 Regenerative Medicine Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Regenerative Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=PN24&utm_medium=002

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Tags: Regenerative Medicine Market Size, Regenerative Medicine Market Trends, Regenerative Medicine Market Forecast, Regenerative Medicine Market Growth, Regenerative Medicine Market Analysis, Regenerative Medicine Market Business Opportunities and Regenerative Medicine Market Outlook

See more here:
Regenerative Medicine Market 2020 Demand with Global Forecast by Top Leading Players: Organogenesis Osiris Therapeutics, Vericel Corporation, Stryker...

Regenerative Medicine Industry Market Forecast 2020-2026

The Global Regenerative Medicine Industry Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Regenerative Medicine Industry Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/94232

The Report Covers the Following Companies:company 1company 2company 3company 4company 5company 6company 7company 8company 9

By Types:Type 1Type 2Type 3

By Applications:Application 1Application 2Application 3

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/94232

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Important Facts about Regenerative Medicine Industry Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/94232

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read the rest here:
Regenerative Medicine Industry Market: Global Analysis Of Key Manufacturers, Dynamics & Forecast 2020-2026 - News Times

A team of UCLA School of Dentistry researchers has developed the first adhesive hydrogel specifically to regenerate bone and tissue defects following head and neck surgeries. Their invention was inspired in part by the way that marine mussels can stick to wet surfaces.

Their research is publishedonline in the journal Science Translational Medicine.

Over the past few years, surgeons and clinicians have begun using hydrogels to administer therapeutic drugs and stem cells to help regenerate lost tissues and bone defects. This approach has advantages over the previous standard treatment, bone grafts, which can lead to inflammation and infection, and which can be costly.

Hydrogels, which are made of networks of polymers, have been found to be effective for carrying drugs and stem cells to targeted spots in the body. But when theyre used during surgeries in the mouth, hydrogels tend to become less effective, because blood and saliva prevent them from properly adhering to a surgical site. As a result, the drugs or stem cells they contain dont stay in place long enough to deliver their regenerating and therapeutic properties.

We knew that we needed a product that had optimal adhesion within the confines of the mouth or else our goal to effectively regenerate bone and tissue in the oral cavity would fail, said Dr. Alireza Moshaverinia, an assistant professor of prosthodontics at the UCLA School of Dentistry and the studys corresponding author.

Taking inspiration from mussels natural ability to adhere to surfaces underwater, the researchers modified their hydrogel by applying an alginate-based solution. Alginates are found in the cells of algae and, when hydrated, form a sticky, gum-like substance.

The researchers tested their new hydrogel loaded with stem cells taken from gum tissue and bone-building bioactive ceramics in an 18-week study on rats with a version of peri-implantitis, an infectious disease that causes inflammation of the gum and the bone structure around a dental implant.

By the end of the study, the bone around the implants in all of the rats had completely regenerated.

The scientists injected the hydrogel in the mouth and, to seal it in place, applied a light treatment, similar to the method dentists use in humans to solidify dental fillings.

The light treatment helped harden the hydrogel, providing a more stable vehicle for delivery of the stem cells, Moshaverinia said. We believe that our new tissue engineering application could be an optimal option for patients who have lost their hard and soft craniofacial tissues due to trauma, infection or tumors.

The studys other authors are Mohammad Mahdi Hasani-Sadrabadi, Patricia Sarrion, Sevda Pouraghaei, Yee Chau, Sahar Ansari, Song Li and Dr. Tara Aghaloo, all of UCLA.

The research was supported by the National Institute of Dental and Craniofacial Research and the California Institute for Regenerative Medicine.

Go here to read the rest:
Hydrogel could be step forward in therapies to generate bones in head and neck - UCLA Newsroom

A cell bank refers to a facility that store cells derived from various body fluids and organ tissue for future needs. The bank store the cells with detailed characterization of the cell line hence decrease the chances of cross contamination. Cell banking outsourcing industry involves collection, storage, characterization, and testing of cells, cell lines, and tissues. Cell banks provide cells, cell lines, and tissues for R&D, production of biopharmaceuticals with maximum effectiveness and minimal adverse events. The process for storage of cells includes first proliferation of cells that multiplied in large number of identical cells and then stored into cryovials for future use. Cells mainly used in the regenerative medicine production. Increasing demand of stem cell therapies and number of cell banks expected to boost the global market.

Global cell banking outsourcing market segmented based on bank type, cell type, phase, and geography. Based on bank type market is further segmented into master cell banking, working cell banking, and viral cell banking. Cell type segment further divided based on stem cell banking and non-stem cell banking. Stem cell banking includes dental, adult, cord, embryonic, and IPS stem cell banking.

For detailed insights on enhancing your product footprint, request for a Sample here @https://www.persistencemarketresearch.com/samples/8026

Based on phase, the global cell banking outsourcing market segmented into preparation, storage, testing, and characterization. Geographically, market divided into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. By considering bank type master cell banking accounted largest share owing to longer duration of preservation that would attract the researcher. Stem cell banking accounted larger share than non-stem cell banking due to lower risk of contamination. In stem cell banking cord stem cell banking accounted larger share by revenue in 2014 due to increasing number of cord blood banks, and services globally.

Additionally, donor convenience, immediate availability, lower risk of viral contamination is major driving factors for cord stem cell banking. In bank phase, segment storage phase accounted largest share and expected to maintain its share due to development of sophisticated preservation technologies such as cryopreservation technique. Geographically, North America accounted largest share due to high number of ongoing research projects. However, Asia Pacific expected to show significant growth during forecast period owing to supportive government initiatives coupled with increasing awareness about cell therapies.

The global cell banking outsourcing market is witnessing lucrative growth during forecast period due to increased research in cell line development owing to rise in incidence of infectious chronic disorder, and cancer. Additionally, development of advanced preservation techniques, increasing adoption to the stem cell therapies, rise in cell bank facilities across globe, and moving focus of researcher towards stem cell therapies would drive the market.

To receive extensive list of important regions, ask for TOC here @https://www.persistencemarketresearch.com/toc/8026

However, high cost of therapies, availability of right donors, and legal and changing ethical issues during collection across the globe are major restraint of the market. Risk associated with cell line banking is contamination of cell lines by manual errors or environmental conditions hence care should be taken during storing and handling of cells.

Major player in cell banking outsourcing market include;

BioOutsource (Sartorious)

BioReliance

BSL Bioservice

Charles River Laboratories

Cleancells

CordLife

Covance

Cryobanks International India

Cryo-Cell International Inc.

GlobalStem Inc.

Goodwin Biotechnology Inc.

LifeCell International Pvt. Ltd.

Original post:
Cell Banking Outsourcing Market to Witness Surge in Demand Owing to Increasing End-use Adoption - Lake Shore Gazette

Regeneron Pharmaceuticals this week initiated test trials of an arthritis drug as a potential remedy for the worst symptoms of COVID-19, the disease caused by the novel coronavirus.

The biotech giant announced Monday it launched a clinical program using Kevzara, a commercial medicine that treats active rheumatoid arthritis, and recruiting hospitalized patients experiencing severe symptoms of the respiratory illness.

"We did something that's never been done in record time," launching a study in New York state "where we're going to already be treating patients with this," Regeneron Chief Scientific Officer Dr. George Yancopoulos told CNBC'sJim Crameron Tuesday.

The Regeneron co-founder and president hopes within a few weeks that results will support findings from China, where health officials tried a variety of medicines to combat the disease as the virus spread quickly. Kevzara is an antibody that could help prevent the lungs from triggering an overactive inflammatory response, Regeneron said.

"The one thing everybody got excited about is something that blocked inflammation. This was done in an uncontrolled way, not a randomized controlled study," Yancopoulos said in the "Mad Money" interview.

Regeneron is working with the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to get the trials underway, he added.

If successful, it could be used as an immediate remedy for patients in critical condition.

"[W]e're going to be hopefully seeing within a few weeks whether this really replicates and confirms the positive suggestions that are coming out of China,"Yancopoulos said. "If they are, it means for the most seriously ill patients we may have something that keeps them from having to go on ventilators or be able to maybe take off ventilators."

Regeneron is working on the clinical program with Sanofi, the French drugmaker leading the study abroad. The biotech companies co-developed Kevzara, which received FDA approval in 2017.

The U.S. trial will launch in medical centers in New York, the state hardest hit by the coronavirus pandemic, and is expected to enroll as many as 400 patients in more than a dozen states. The second phase of the program will study long-term outcomes, according to a press release.

"This could in a very short time give hope to the most critical people,"Yancopoulos said.

Outside of the Kevzara trial, Regeneron announced Tuesday it plans to begin testing a coronavirus antibody treatment on humans sooner than once expected. The company moved its timeline up for human testing from late summer to early summer.

There are more than 7,300 confirmed cases in the United States as of Wednesday afternoon, according to data compiled by Johns Hopkins University.

Read the original post:
Regeneron to treat coronavirus patients this week in trial using its rheumatoid arthritis drug - CNBC

Pharmaceutical companies and research facilities are working to find new, successful treatments for those infected with coronavirus. But clinical trials and FDA approval can take time, so while new drugs are being developed, companies are seeing if older drugs can be repurposed.

Heres a list of some of the options being explored and why they might be useful in blunting the effects of coronavirus.

Doctors in China have used an anti-inflammation drug to curb the effects of the coronavirus on critical patients, and now the maker of the drug says it is talking to the Food and Drug Administration about clinical trials.

Tocilizumab, sold under the name Actemra and made by the Swiss pharmaceutical firm Roche, is a prescription medicine used to treat adults with moderate to severe active rheumatoid arthritis, as well as certain types of juvenile arthritis.

Chinese doctors have used Tocilizumab to prevent an overreaction of the immune system that has led to organ failure and death in coronavirus patients. An initial clinical trial in China used Actemra in 20 severe COVID-19 cases. Nineteen of the patients were discharged from the hospital within two weeks and one got better, according to Chinas National Health Commission. The drug has now been approved for use in China, but has not yet been approved in the United States.

Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.

Karsten Kleine, a spokesperson for Roche, told NBC News that the drug company is in active discussions with the FDA, as well as government bodies and institutions around the world, to initiate clinical trials that evaluate the safety and efficacy of Actemra (tocilizumab) for the treatment of severely ill COVID-19 patients.

Roche is not alone in looking into rheumatoid arthritis drugs as a potential treatment. Sanofi and Regeneron are launching a clinical trial in New York to see if their rheumatoid arthritis drug Kevzara is effective.

AbbVie, the creator of HIV drugs Kaletra/Aluvia, is collaborating with health authorities to determine the efficacy of using its HIV drugs to treat COVID-19. The company is working with the FDA, CDC, and European agencies to set up clinical trials of the drug.

At this time, AbbVie told NBC News it cannot confirm Chinese media reports that the drug has been successful in treatment as it does not have access to Chinese clinical information. It is monitoring its current supply to make sure current HIV patients being treated by the drug will not be affected by an increase in demand.

Sanofi is assessing the risk and benefit of its malaria drug hydroxychloroquine for the management of coronavirus. According to the company, some health authorities are allowing the temporary use of chloroquine for the management of COVID-19, but there is insufficient data to draw any conclusions over its efficacy. Any use of the drug in this context is considered off-label use.

Based on encouraging preliminary findings from a study in France, Sanofi is looking at ways to collaborate and partner with health authorities investigating the use of hydroxychloroquine for the management of coronavirus.

Remdesivir is a broad spectrum anti-viral medication developed by Gilead Sciences as a treatment for Ebola and also showed success in treatment of monkeys infected with MERs, a different type of coronavirus. It is now being tested as a potential COVID-19 treatment.

Remdesivir is in clinical trials in China and the U.S. at the University of Nebraska Medical Center. There are 20 locations involved in the trial and seven are recruiting for participants, including Emory Vaccine Center in Atlanta and The University of Washington Virology Research Clinic. All participants must have laboratory-confirmed SARS-CoV-2 infection with symptoms showing evidence of lung involvement, rattling sounds when breathing with a need for supplemental oxygen or abnormal chest X-rays, or illness requiring mechanical ventilation.

The first participant is an American who was on the Diamond Princess cruise ship that docked in Yokohama, Japan.

Those with a confirmed infection who have mild symptoms or no apparent symptoms at all cannot participate in the study.

Emily Siegel is an associate producer with the NBC News Investigative Unit.

Originally posted here:
Here are some of the existing drugs that may be repurposed to treat coronavirus - NBCNews.com

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - P&T...

After careful consideration, the American Academy of Allergy, Asthma & Immunology canceled its annual meeting that was to take place in Philadelphia, Pennsylvania from March 13 to 16, because of concerns regarding the coronavirus disease 2019 (COVID-19) outbreak. Although the live events will not proceed as planned, our readers can still find coverage of research that was scheduled to be presented at the meeting.

Drug reaction with eosinophilia and systemic symptoms (DReSS) with exposure to interleukin (IL)-1 or IL-6 inhibition may be linked to high fatality lung disease and poor outcomes in systemic juvenile idiopathic arthritis (sJIA), according to research intended to be presented at the American Academy of Allergy Asthma and Immunology (AAAAI) annual meeting.

Using REDCap databases, researchers collected retrospective observational data for 63 patients with sJIA with lung disease who were diagnosed by 55 physicians from 39 institutions. Researchers evaluated DReSS in patients by using the validated RegiSCAR scoring system.

Of the 63 patients with sJIA and lung disease, 48 had unusual high fatality lung disease associated with IL-1 or IL-6 inhibition. A total of 15 patients were scored with definite DReSS (score, >5/9) and 8 with probable DReSS (score, 4-5/9). At the time of eosinophilia diagnosis, all 23 patients had been exposed to 1 medications, including anakinra, tocilizumab, canakinumab, and rilonacept. Despite concurrent steroid treatment (0-2 mg/kg/d), median peak peripheral eosinophil count was 1725 (range, 754-13,156; 6%-45% of white blood cells) in patients with definite DReSS; facial rash with angioedema was reported in 12 patients.

Among patients in the definite DReSS group, 8 patients stopped the suspected medication, of whom 6 survived (median survival since lung disease diagnosis, 4.7 years) and 2 died after restarting the medication. The remaining 7 patients who continued the medication died.

Overall, the researchers concluded that, DReSS with lung involvement is a high fatality illness. Unrecognized DReSS with exposure to anti-IL-1/IL-6 may account for lung disease and poor outcome in some sJIA cases.

Reference

Saper V, Mellins E, Kwong B. Drug reaction and high fatality lung disease in systemic onset juvenile idiopathic arthritis (sJIA). J Allergy Clin Immunol. 2020;145(Suppl 2):AB95.

This article originally appeared on Pulmonology Advisor

Read more:
DReSS Linked to High Fatality Lung Disease in Juvenile Idiopathic Arthritis - Monthly Prescribing Reference

The situation in Italy is dire when it comes to COVID-19 currently with more than 1,000 deaths. Authorities and science are doing the impossible to make progress in combating this virus. Tocilizumab is a drug that treats moderate to severe rheumatoid arthritis. It can also treat polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA).

Now its being tried on COVID-19 and with some encouraging results.

A Chinese -Italian Team in Napes, Italy has been experimenting with this drug to fight Covid-19. This news was spread in the Italian press and from the sources of Italian secure communications: RAI-TV

A collaboration between the Colli Hospital, the Cancer Institute of Naples and Chinese doctors, it was verified that Tocilizumab can give positive results in the care of people infected with Coronavirus.

Two patients from Naples immediately responded

The drug was administered to two patients hospitalized at Cotugno Hospital (in Naples), suffering from severe Covid-19 pneumonia last Saturday. 24 hours after the infusion, encouraging improvements were highlighted, especially in one of the two patients, who arrived at the hospital as a particularly critical case. This was reported by the Neapolitan hospital of the Hills.

The same drug has been used in China in 21 patients and now for the first time has been administered in Italy in Coronavirus patience.Based on this experiment it is currently evaluated if treating other critically ill patients is recommended.

The International team

The result was made possible thanks to a great team effort mentioning: the Oncology of the Azienda dei Colli by Vincenzo Montesarchio, the Oncological Immunotherapy and Innovative Therapies of Pascale by Paolo Ascierto together with the virologist Franco Buonaguro, and some Chinese doctors, including Wei Haiming Ming from the First Affiliated Hospital of University of Science and Technology of China as well as the team of doctors from Cotugno, composed among others by Rodolfo Punzi, director of the department of infectious diseases and infectious diseases, Roberto Parrella, director of Uoc Diseases respiratory infectives, Fiorentino Fragranza, director of the Uoc Anesthesia resuscitation and intensive care, Vincenzo Sangiovanni, director of the Uoc Systemic infections and immunosuppressed, Nicola Maturo, head of the Infectivology First Aid always by Cotugno and Luigi Atripaldi, director of the Microbiology laboratory and virology.

The Chinese experience

Paolo Ascierto and Vincenzo Montesarchio explained out how 21 patients had been treated. All of them showed a visible improvement already in the first 24-48 hours after treatment. Treatment included a single solution It acted without interfering with the protocol therapeutic use based on antiviral drugs.

The downside:

According to Gunther Franke, a pharmacist in Cologne, Germany this news may be good also for Roche Pharma, the manufacturer of the medicine. 4 injections sell for 1900,00, 12 injections for 5800,00

More here:
Arthritis Drug Being Tried on Italian Coronavirus Patients - The St. Kitts-Nevis Observer

As anyone who lives with a chronic illness knows, the plans you have for your life cant always be counted on. Sometimes, theres no amount of trying that will ever be enough to meet those hoped-for goals. And sometimes, you have to let your body lead the way to a future your never imagined.

In 2010, Kirsten Schultz, now 31, was working on a masters degree in Islamic studies and Arabic language at the University of Wisconsin in Madison. Their ultimate goal? To make a difference in the world by working as a diplomat. (Schultz uses the pronoun they). And theyd gotten this far by sheer determination. Schultz had literally clawed their way through college, fighting symptoms of rheumatoid arthritis every step of the way. Not only did they work multiple jobs, Schultz battled frequent illnesses and disease flares. But by the time they began work on their graduate degree, new medication had gotten Schultzs symptoms mostly under controluntil they werent.

Like most treatments for RA, Schultzs medication works to suppress the overactive immune response thats causing the joint pain and inflammation; as a result, patients are often more vulnerable to infections. And during grad school, Schultz seemed to get anything and everything that was floating around campus.

Professors docked points when they missed classes, which happened frequently. Some days Schultz just couldnt get there. Daily Arabic classes really required near perfect attendance and missing even one day a week meant a lot of makeup work, Schultz explains. On weeks where I missed more than one day, I was honestly just a body in a classroom. Physically and emotionally, I felt like I was drowning.

Battling these illnesses on top of the fatigue, pain, and brain fog that was just part of living with their arthritis eventually made it almost impossible for Schultz to manage their course load. Something was going to have to change. After 18 months of struggling, they decided to withdraw from school in 2012.

Everything I had worked for for so long, I couldnt do anymore, Schultz says. Dropping out of school was one of the hardest things Ive ever done. As someone who loves learning, being unable to continue studying a subject I was incredibly passionate about was devastating. To admit I was sick enough to have to stop school alone was incredibly hard to do. Many people with disabilities struggle with coming to terms with limitations that we face, and this was that moment for me.

And over the next year, Schultzs depression grew deeper. A close friend had died. Their dream of having a career in world diplomacy was over. And their body just kept letting them down. But somehow, from somewhere deep inside, there was a little voice that told them not to give up.

One of the first things Schultz did was put their energy into their blog. It was an outlet for me to process what I was dealing withand help others by talking about it, they explain. Researching topics to write led me to writing for other organizations and to some really cool opportunities such as attending conferences using a press pass.

They also started volunteering, just a few hours a month at first, with the Arthritis Foundations Arthritis Ambassador Group as way to help enact change, and soon was invited to speak at events.

After that, my volunteering picked up, Schultz says. I was working with not only the AF but also with the International Autoimmune Arthritis Movement, National Arthritis Research Foundation, and other arthritis-based orgs. Doing all this helped me truly feel like I was giving back.

By 2014, Schultz felt like their life was starting to pick back up. They got married, continued with their advocacy work, and even started a new job at the local medical school, which opened their eyes to whole other side of health care, especially the quality-improvement process. Seeing what happens on the healthcare-system side and combining that with what I've seen from the patient side pushed me to want to help improve the overall system, they say.

Schultz had found a new path, perhaps the one they were always meant to follow. In 2015, they began a new masters degree in health administration with a focus on patient advocacy. But this time, they enrolled in an online program to better protect their health.

"Going to school online was such a better fit for me, Schultz says. I could work on classwork, group projects, and attend virtual classes without having to worry about germs, parking, or even wearing pants! Once I got back into the grove of attending classes, I felt amazing. The excitement that I have always felt about learning came back and, for the first time in three years, it felt like my brain fog had lifted."

Finally, in 2017, Schultz earned their degree. "To go from being unable to finish my previous attempt to finishing this one that meant so much more to me personally because of the subject matterits something that I can't describe in words very well. Just knowing I was smart enough and could accomplish this was well worth the degree."

But even with this huge accomplishment to launch them into their next chapter, Schultzs health pulled them back once again. On top of their RA symptoms, Schultz was diagnosed with two additional conditions, hypermobility syndrome, which had been causing increased joint pain, and mast-cell activation syndrome (MCAS), an immunological condition that can cause anaphylaxis and near-anaphylaxis.

The hypermobility was something that I have always had, but it was never diagnosed, Schultz explains. The MCAS makes them extremely sensitive to certain common chemicals. I cant walk down the detergent aisle in the supermarket because I cant take the fumes. Just breathing in certain products triggers symptoms of mild anaphylaxis for me.

For a while, Schultz opted to work part-time and continue advocating for other people via their websites. Along with their blog, they founded Chronic Sex.org, an online forum for people who have disabilities to discuss and learn about sexual issues. Schultz got the idea after attending an Arthritis Introspective conference at which they realized that a lot of the attendees, old and young alike, didnt really know much about basic sexual education. I realized how many people with disabilities get excluded from sex ed, and I wanted to start a forum to help change that, Schultz recalled.

Schultz has traveled internationally to speak at conferences, launched a podcast, and is in the process of developing a Chronic Sex research arm, called ORCHIDS: The Organization for Research on CHronic Illness, Disability, and Sexuality. Then last year, Schultz got their dream job working for a nonprofit dedicated to advocating for the rights of people with disabilities.

"I feel very honored to [help] create positive change. While working in health and sexuality are completely different than what I expected to be doing when I finished my undergraduate degree, I've been able to find ways to still do things I enjoy like research and giving talks, Schultz says. Being able to take on projects and get grants has been wonderfully emotionally. These were things I didn't think I'd be able to do in 2012, and I feel very lucky. My health is still an issue, but thankfully it gets to be on the backburner more days than notand that's pretty great."

Also pretty great? Schultzs journey with arthritis helped them discover another passion. Theyd been in physical therapy when theyd discovered a local LGBTQ hockey team. Throughout their work with Chronic Sex, Schultz had learned a lot about who they were, too, including that they were non-binary and pansexual. Their marriage had ended partly as a result.

"I had been so sick all the time and always had to figure out how to manage my health issues, Schultz explains. I never really had time to have a social life and, with the divorce, I needed to fix that. So Schultz ask their P.T. if itd be safe to play, and the therapist was 110% supportive, Schultz recalls.

The first day of hockey was comical, and I was very sore afterwards, Schultz says. I mean, here I am living with arthritis and my body doesnt move correctly anyway, and there I am standing on skates on the ice. But I loved it and, even though I only skated for five minutes of the entire hour, I couldnt wait to go back.

Schultz plays goalie, a position that taught its own set of lessons. They say: As goalie, I have learned that one night you can stop every puck and another night, you can stop none. There is a lot of luck involved. I think knowing this has made it a lot easier for me to let go and not feel like I have to be in control all the time.

The team has also been a source of new friendships. The amount of support that I have gotten has been incredible, Schultz says. Having a really large group of people to lean on for support has been completely life-changing.

Schultz always likes to have a plan in place, and theyre feeling good as they look forward to the years ahead: I am still going with the notion of not putting a lot of expectations on myself and on what my future looks like, they say. But I've started to work with my body more often than against it. Funny enough, part of teaching other people about self-love and self-esteem has meant having to learn what I teach! That alone has been worth this entire journey. Instead of getting upset at my body, I give myself space and graceto mess up, rest, and try again tomorrow."

See the rest here:
They're Back in the Game - HealthCentral.com

NewsHealthLeading scientists believe 'hyperinflammation' drugs could help with worst cases of the virus

Sunday, 15th March 2020, 6:50 pm

Existing drugs for rheumatoid arthritis and cases of excessive inflammation could be used to treat some of the most severe cases of coronavirus, leading scientists say.

A recent study into coronavirus deaths in China suggested that many of the fatalities were caused by an overactive immune response in the body that was triggered by the virus - rather than by the virus itself.

This suggests that existing drugs designed to suppress these kind of overreactions in the immune system - known as 'hyperinflammation' or cytokine storms - have the potential to significantly reduce casualties from Covid-19.

However, clinical trials are needed to confirm whether these drugs are an effective coronavirus treatment, according to a panel of scientists and clinicians researching the issue.

Screen worst-hit patient

The researchers recommend that all patients who are suffering badly from coronavirus be screened for hyperinflammation with a blood test - and given steroids or other approved drugs if they are found to have it.

Deaths from Covid-19 are rising and there is an urgent need for effective treatment. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality, Puja Mehta, of University College London, told i.

Improving awareness of the risk of hyperinflammation and treating patients with immunosuppression therapies is likely to be important in the pandemic, she said.

"Deaths from Covid-19 are rising and there is an urgent need for effective treatment,"

Puja Mehta

Dr Mehta was speaking on behalf of a collaboration of five hyperinflammation experts from universities and hospitals across the UK. They have written an article for The Lancet journal, seen by i, outlining their case.

Immunosuppressants such as the rheumatoid arthritis treatment Actemra, anti-inflammatory 'cortico' steroids and intravenous immunoglobulin blood treatments are used to dampen the immune response and save lives.

Study of Chinese cases

A recent study into 150 cases of Covid-19 cases in China found a link between fatal cases of coronavirus and cytokine storms.

It is recognised that some patients with severe Covid-19 may have hyperinflammation which can be picked up by blood tests.

Where hyperinflammation is shown this is associated with severe coronavirus symptoms and may predict death, Dr Mehta said.

During a cytokine storm, an excessive immune response ravages healthy lung tissue, leading to acute respiratory distress and multi-organ failure. Untreated, cytokine storm syndrome is usually fatal.

Trial of arthritis treatment

Chinese authorities have approved the use of the Actemra rheumatoid arthritis treatment for lung damage arising from coronavirus.

Meanwhile, Chinese researchers have started a trial to assess the safety and effectiveness of using the drug in coronavirus patients with cytokine release syndrome.

Here is the original post:
Existing drugs may have a key role to play in coronavirus treatment - inews

X-rays are generally a good guide to whats wrong with your hip, however it may be difficult to get complete assessment of X-rays especially in early disease, where the changes in the bony architecture may not be easily visible. Magnetic Resonance Imaging (MRI scans) are a great tool to assess the disease process and formulate plan of treatment.

Treatment plan

Once the complete assessment is done, the treatment plan is outlined based on the problems faced and the amount of pain and disability the patient has due to arthritis.

In early disease, the treatment starts with changes in the lifestyle and anti inflammatory medicines. Patient should avoid sitting on the floor and squatting. They are motivated to maintain their muscle strength and hydrotherapy and swimming are a good way to maintain movement and stamina without further damaging the already diseased joint.

A good physiotherapy protocol is formed to give them better quality of life in future. In cases of proven Rheumatoid Arthritis and Ankylosing Spondylitis, a Rheumatology specialist opinion is helpful to give them course of Disease Modifying Medicines. They help in control of the arthritis and delay the surgery to a certain extent.

When there is damage to the blood supply, medicines to reduce the blood coagulation may be effective. The aim of the non operative management is to maintain the hip strength and flexibility, and even after taking all the precautions, the disease may progress gradually to a level where a surgical intervention is needed.

When the arthritis gets worse, the patient may have to undergo some surgical intervention to be able to mobilise and lead pain free life. Although difference types of surgeries are available, you may have to head to total knee replacement in severe disease.

The results of the procedure are very predictive and patients lead nearly normal and productive life after undergoing the surgery. They get pain free range and mobility and good quality of life after surgery.

The prosthesis and bearing surfaces have also evolved over decades and the invent of Ceramic and Oxynium heads have given us hope for increased survival of the replaced joint for longer term.

And the newer cement-less designs have better integration into the bone and enable to get fixation without cement, thereby nullifying cement related problems.

If you have hip problems in early age, do visit your orthopaedic surgeon to find a right solution. Timely treatment could help delay surgery and maintain good quality active life.

Go here to read the rest:
Combating arthritis: How to deal with this crippling disease - Free Press Journal

Stories @ Gilead

When Julie Di Paolos father was diagnosed with Crohns disease, an inflammatory condition with limited treatment options, it sparked curiosity and drive that have carried forward into her career at Gilead, where she is Executive Director of Inflammation Biology.

I realized how few medications were being developed to treat the drivers of inflammatory diseases, and how far away the field was from delivering curative therapy, she recalls. That still sticks with me today.

Julie joined Gilead in 2010, as the company was further expanding its work outside of antivirals. While there have been moderate advances in disease understanding and treatment options, significant unmet needs remain for people living with inflammatory conditions. An estimated 38 million people around the world live with inflammatory diseases and two-thirds of patients do not achieve the current treatment goal of disease remission. According to Julie, progress is being made but much more is still needed.

Rheumatoid arthritis is an example of an inflammatory disease where a lot of the underlying pathways arent well understood, Julie explains. When someone is diagnosed, its not clear whether a particular therapy is going to work for that person. Its essentially a process of elimination until the physician and patient find the right option. Really pairing the right therapy with the right individual is the aspirational place that we want to go. We want to get a much deeper response, and bring relief to more people.

Julie and her team research a broad range of inflammatory diseases, with particular focus on studying small molecules that have the potential to inhibit the Janus kinase (JAK) family of four proteins, some of which are highly active in inflammation. Inhibiting these proteins, particularly JAK-1, has the potential to reduce inflammation, associated symptoms and disease progression.

While there is still much work to be done to fully understand the complex pathways that contribute to inflammatory diseases, Julie says headway is being made.

It starts with incrementally making progress toward understanding a disease and seeing how you can chip away at getting better responses to treatment, Julie says. The ultimate goal is to eventually get to a place where the disease is so well-maintained that it no longer impacts a persons quality of life.

Julie and her team are approaching inflammation from all sides, in what she calls an ABC treatment paradigm. The objective is toArrestthe disease, or stop it where it is and prevent it from getting worse. From there, the next step is toBalancethe condition by creating a tolerogenic environment and reducing the source of inflammation. Eventually, the team believes it will be necessary toCombinetreatments to achieve long-term control of many inflammatory diseases.

Recent progress has enabled Gilead to submit an investigational JAK-1 inhibitor for regulatory review in the United States, Europe and Japan. Addressing the existing gaps in the current standards of care also require partnerships, says Julie, pointing to Gileads 10-year global research and development collaboration with Galapagos. Scientists from the two companies are working together closely to discover and develop potential new therapies.

In science, its all about finding the truth, Julie says. These types of partnerships help create new possibilities for people living with inflammatory diseases. They allow us to bring all of the best ideas together and work collaboratively to advance those that make the most sense.

Originally posted here:
Profiles in Creating Possible: Julie Di Paolo is on a Mission to Understand Rheumatoid Arthritis and Other Inflammatory Diseases Press Releases on -...

Zion Market Researchalways aims at offering their clients an in-depth analysis and the best research material of the various market. This new report on theGlobal Psoriatic Arthritis Therapeutics Market Is Expected To Reach Around USD 16.71 Billion By 2025is committed fulfilling the requirements of the clients by giving them thorough insights into the market. The Psoriatic Arthritis Therapeutics Market report, titled Psoriatic Arthritis Therapeutics Market, is expansive research reliant on Psoriatic Arthritis Therapeutics Market, which inspects the raised structure of the present Psoriatic Arthritis Therapeutics Market all around the globe. Arranged by the adequate methodical framework, for instance, SWOT examination, the Psoriatic Arthritis Therapeutics Market report exhibits a total evaluation of the significant players of thePsoriatic Arthritis Therapeutics Market. The estimates for CAGR (Compound Annual Growth Rate) is calculated by the Psoriatic Arthritis Therapeutics Market report in terms of extent for the specific time length. This will similarly help the customer with comprehension and settle on a correct choice depends on a normal chart.

Request Free Sample Report of Psoriatic Arthritis Therapeutics Market Report @https://www.zionmarketresearch.com/sample/psoriatic-arthritis-therapeutics-market

Some of the Major Psoriatic Arthritis Therapeutics Market Players Are:

AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company

This report similarly comprises of the bifurcation of the Psoriatic Arthritis Therapeutics Market by the type of product, its end-users, applications, and others . Moreover, Psoriatic Arthritis Therapeutics Market report gives an arrangement regard to the Psoriatic Arthritis Therapeutics Markets components, by pinpointing a couple of edges including limitations, regard chain, utilization foundation, and client affirmation. The Psoriatic Arthritis Therapeutics Market report is assembled of direct experiences isolated from the emotional and quantitative assessment by Psoriatic Arthritis Therapeutics Market agents, competition between them, strategies, Psoriatic Arthritis Therapeutics Marketing, production, research, and development. Moreover, Psoriatic Arthritis Therapeutics Market report addresses a methodical appraisal of macroeconomic markers, parent Psoriatic Arthritis Therapeutics Market inclines and developed components together with the Psoriatic Arthritis Therapeutics Market.

Also, the emotional effect is charted by the examination of different provincial regions[Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]together with segments. The Psoriatic Arthritis Therapeutics Market globally is the cornerstone of the development angles and prospects, as the improvement of a specific arrangement needs numerous mechanically upheld hypothesis, thoughts, and systems. The Psoriatic Arthritis Therapeutics Market report contains in general successful system, confinements, and top to bottom illumination of the past information alongside the present and future needs that might concern the development. The Psoriatic Arthritis Therapeutics Market report affirms an exhaustive synopsis of the present development, variables, enumerating, and creation. The Psoriatic Arthritis Therapeutics Market report additionally conveys a total dynamic of the money related good and bad times concerning request rate and satisfaction proportions.

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/psoriatic-arthritis-therapeutics-market

Promising Regions & Countries Mentioned In The Psoriatic Arthritis Therapeutics Market Report:

Following 15 Chapters represents the Psoriatic Arthritis Therapeutics Market globally:

At last, the global Psoriatic Arthritis Therapeutics Market gives the readers a complete view of the market during the forecast period from 2020-2026 which will assist them in making right business choices that will lead to development the development of their company.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/psoriatic-arthritis-therapeutics-market

Worldwide Psoriatic Arthritis Therapeutics Market Report Provides Comprehensive Analysis of:

Questions covered in Worldwide Psoriatic Arthritis Therapeutics Market Industry research report:

What are current global Psoriatic Arthritis Therapeutics Market market tendencies, obstructions, and challenges faced by the key competitors of Psoriatic Arthritis Therapeutics Market market?

What are major outcomes and consequences of the five strengths study of Psoriatic Arthritis Therapeutics Market industry?

What will be the Psoriatic Arthritis Therapeutics Market market capacity and growth estimation forecast up to 2026?

Who are the major players in the world Psoriatic Arthritis Therapeutics Market market and what ways they follow to increase overall revenue?

What are the durabilities and defects of the Psoriatic Arthritis Therapeutics Market industry?

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/psoriatic-arthritis-therapeutics-market

Reasons to buy:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Follow this link:
Global Psoriatic Arthritis Therapeutics Market To Witness Towering Growth And Surpass USD 16.71 Billion By 2025 - Bandera County Courier

With a viral outbreak prompting the WHO to declare a global health emergency, let's take a look at what a coronavirus is. Louisville Courier Journal

There are points in our history that we'll always remember.

For some, it was the Kennedy assassinations. Both of them. Or when MLK was gunned down. For others, the Nixon resignation. Or the Challenger explosion, or the attack on the World Trade Center.

We can now add the coronavirus to the list of events that have changed our outlooks, inexorably altered the path of our country and forced us to take stock in our own lives.

"I'm shaking," said Frank Foster, ashe held court Thursday at the big round table in the middle of Franco's Restaurant, which he opened13 years ago. He admitted feeling helpless if the pandemic spikes here as it did in Wuhan, China, and Milan.

"I wouldn't know what to do," the 78-year-oldsaid."I've never been through anything like this before."

There's a good reason he was shaking. A lot of us were.

That day Thursday was the most memorable awful day of a memorable awful week.The news was filled with dire warnings from our elected officials.

Frank Foster, right, the owner of Franco's, said he is "shaking" because of the coronavirus.(Photo: Joseph Gerth)

[Want to know all the Kentucky-related coronavirus news? Download our app.]

That day saw the Dow Jonesplummet2,353 points the worst drop since the stock market crash of 1987. It saw schools throughout the state begin to close as we try to protect our children from catching the virus and bringing it home to sicken us and theirgrandparents.

That horrible day saw more and more things like plays and concerts events where we gather to have fun and celebrate life put on hold.

Considered impossible just a couple of days earlier, the Kentucky High School Athletic Association called off the Sweet Sixteen basketball tournaments.

And perhaps in the most stunning move of all for us, it saw the NCAA cancel March Madness, do away with spring sports altogether, and it saw most major professional sports suspend or delay their seasons.

By Saturday, Kentucky had at least 16 positive tests for the coronavirus.

Gov. Andy Beshear has consistently warned us that there will be more.

While we haven'thad any of the deaths here like in Washington and California and a few other states, it'shard to imagine the coronavirus hasn't stolen from each of us something we love whether it's learning or sports or our ability to retire. Or if it's just our peace of mind.

Mark Rucker, a 50-year-old real estate lawyer in Lexington, is worried.

About 80%of the people who get COVID-19 have mild or no symptoms, according to the World Health Organization. But older adults and people with serious chronic medical conditions including heart disease, kidney disease, diabetes and lung disease are at higher risk, according to the Centers for Disease Control and Prevention.

Kentucky coronavirus live updates: Get the latest information here

He's in the 20% none of us wants to be in.

Rucker has kidney disease andrheumatoid arthritis, which requires him to take a steroid that suppresses his immune system.

On Monday, the news came that the first positive test for the coronavirus had been reported in Lexington. This had him especially on edge.

So on Tuesday morning, he got up and went to his kidney doctor for a previously scheduled appointment.

"I wore an N95-rated mask to my appointment for the first time ever," he said. "I did feel slightly awkward but again, being around other immune-compromised individuals just really made me think 'better safe than sorry.'"

It's scary for many people.

State officials are telling people to stay away from crowds. They're telling us to keep 6 feet between us and others. It's up to that distance that a cough or a sneeze will pose a risk to others. If you're over age 60 or in poor health, you're told not to get on a plane, and for gosh sakes, everyone stay away from cruise ships.

Employers are telling many of us not to go to the office where we can spread the disease. I'll be filing columnsfrom my recliner most days for the next few weeks; my wife will be on her computer across the room; and my daughter will probably be holed up in her bedroom.

Apple Stores have shut down. Others will likely follow.

Some people have gone overboard. Fear has caused them to hoard groceries and toilet paper.

Coronavirus tracker: How manycases are in Kentucky? Where are they?

Autoplay

Show Thumbnails

Show Captions

This will go on for weeks, if not months, as a vaccine isn't expected to be ready until later this year.

The dregs of society are trying to profiteer. One man in Tennessee had amassed 17,700 bottles of hand sanitizer and was selling them for many times their original value before Amazon and eBay stopped price gouging on their platforms, The New York Times reported.

Heshould choke on a bottle of Purell.

Hoarding begets hoarding. Others started buying up everything in groceries. Pasta. Bread. Rice. Toilet paper. Hand soap. Lysol Wipes. Even fresh fruit, which one would think would rot before hoarders eat it, was wiped out in grocery stores.

At Kroger on Friday, I looked around at the empty shelves and felt I knew what it was like to live in the old Soviet Union.

Delta Air Lines announced Friday that it was grounding 40% of its flights as people avoidcommercial carriers.

For someone like Mike Goetz, deciding whether to travel or to be in large crowds could be a life or death decision. He was diagnosed with leukemia about a year ago.

Because of the virus, Goetz and his wife have decided not to fly to Palm Springs, California, this month for a family vacation they had been planning.

My hematologist said, I dont want you on a plane right now. I dont think its prudent,'" Goetz said.

Now, the family is struggling about whether to cancel his daughters March 28 wedding in Nashville, Tennessee.

"Ive had quite a few older family members inform me in the last few days that they wouldnt be coming, he said. Ive never seen such a fluid situation and things changing so quickly in my life.

Read more: Louisville stores flooded by shoppers panicked over coronavirus

Steve Hankins, of Shepherdsville, isn't going to be traveling either.

He was in Saugus, Massachusetts, on business last weekend when he fell ill.

A cough. Shortness of breath. Fever.

He awoke in his hotel room last Sunday morning and drove his rental car to Massachusetts General Hospital and asked a security guard outside where he could find the emergency room.

"STAND RIGHT HERE!" was the order.

Within minutes, someone from the ER gave him a mask and escorted into an isolation room, where doctors began working to figure out what was going on. They determined he had chronic obstructive pulmonary disorder and a bad case of the flu and admitted him to the hospital.

Back in Shepherdsville, his wife was frantic.

Also: As coronavirus fears spread, these small businesses stand to lose big

Why wasn't Hankins, who travels by commercial plane several times a month and passes through airports often,tested for the coronavirus?

The fact is, there just aren't enough tests to go around. People who should be tested aren't being tested.

Only about 150 people in Kentucky have been testedbecause the federal government was slow to react to the burgeoning crises. Because of that, hundreds, or even thousands, of people may be unwittingly spreading the virus in Kentucky.

The virus has interfered with even the simple things in life.

Churches have canceled services.

People are not allowed to visit family in nursing homes unless their loved ones are near death. The rules, necessary to keep the virus away from those most vulnerable to it, are certainly increasing the loneliness and isolation that is already a problem the elderly face.

Some restaurants are empty.

On Friday, Hooked on Frankfort, a fish restaurant within 1.8 miles of five Catholic churches, had only about 15 people eating there at 12:30 p.m. On a Friday. During Lent.

College and university closures were affecting high school students who were planning trips to campuses across the country.

Elise Williamson, a 17-year-old senior at duPont Manual High School,said she learned at about 11 a.m. Tuesday her visit to Yale next month wouldn't happen. She was scheduled to go to New Haven, Connecticut, to learn about financial assistance available to her and then to attend Bulldog Days a three-day orientation program for admitted students.

They were canceling because of the coronavirus, just because of how many students would be coming there, not just from across the country but from around the world, she said.

Williamson said shes disappointed because she thought the orientation programwould have eased her transition to college life, but she said shes in a better position than many students because she was able to visit campus last summer.

Elise Williamson is a senior at Manual High School. She'll be attending Yale University in the fall and had planned an upcoming visit to the school, but it was canceled due to coronavirus precautions.(Photo: Pat McDonogh, Courier Journal)

Dive deep: With coronavirus kits limited, Kentucky is testing only the sickest patients

Law schools at Harvard and University of California, Berkeley, havesaid they aren't sending students to a program at the Appalachian Research & Defense Fund, AppalReD, that helps poor people with their legal troubles and provides an important learning experience for the future lawyers.

On Saturday morning, students at Bellarmine University packed up their belongings and loaded them into cars ordered by the school to vacate the dormitories this weekend.

Wiley Carr III needed only three bags to move out of his dorm room at Bellarmine University: One had his laptop and other class materials. One had some personal hygiene products. The third carried his trumpet.

I understand the safety precautions, Carr,23,said. But this impacts so many students.

Wiley Carr III carried a few belongings after checking out of his dorm on the campus of Bellarmine University on Saturday.(Photo: Sam Upshaw Jr./Courier Journal)

Beshear, who's shown a steady hand warning of the dangers of the virus, has been careful to say at each press conference he's held that "we will get through this."

It's no doubt we will. But it will take its toll.

But we will be forever changed.

We'll think twice about shaking hands for a long time. We'll worry about the next new disease that comes along. And we'll worry if our government will be able to deal with it if it does.

But, as Beshear says, we will get through this.

Information for this column was also gathered by Jonathan Bullington.Joseph Gerthcan be reached at 502-582-4702 or by email atjgerth@courierjournal.com. Support strong local journalism by subscribing today:courier-journal.com/josephg.

Read or Share this story: https://www.courier-journal.com/story/news/local/joseph-gerth/2020/03/14/gerth-covid-19-take-toll-but-well-get-through/5009893002/

Read more:
Gerth: Coronavirus outbreak will take its toll, but we'll get through it as we always have - Courier Journal

An initial triple steroid/intravenous immunoglobulin (IVIG)/steroid-sparing immunosuppressant (SSI) induction strategy was effective for the treatment of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (anti-HMGCR) myopathy, according to study results published in Arthritis Research & Therapy. In addition, early treatment initiation was associated with greater odds of successful maintenance with SSI monotherapy.

Investigators abstracted data from the Phenotype, Serology, and Successful Monotherapy Maintenance in Autoimmune Myositis (PHESMO) study, a retrospective study of patients with autoimmune myositis who received care at 2 participating hospitals in Quebec, Canada. Patients were followed up longitudinally between 2001 and 2018. The current analysis used data from patients with statin-induced anti-HMGCR myopathy, defined as having a positive anti-HMGCR autoantibody test, elevated serum creatine kinase levels, and proximal skeletal muscle weakness. Demographic and clinical data were extracted through medical record review, and therapeutic strategies used to combat anti-HMGCR myopathy were assessed. Multivariate logistic regression was performed to identify predictors of maintenance with SSI monotherapy. Sensitivity analyses adjusted for age, sex, strength, creatine kinase levels, dysphagia, and corticosteroid use.

Data from 55 patients with anti-HMGCR myopathy were used for the study. Median age at diagnosis was 67.7 years; 95% of patients were white; and 72% had diabetes mellitus. The most commonly prescribed statin was atorvastatin (84%). Statin therapy was discontinued in all patients. At initiation of anti-HMGCR myopathy treatment, 46 patients (84%) presented with proximal weakness, 48 (87%) had biopsy evidence of necrotizing myopathy, and all patients were positive for anti-HMGCR autoantibodies. Median creatine kinase elevation was 5000 U/L (range, 554-23,000 U/L).

Overall, 14 patients (25%) achieved remission with a corticosteroid-free induction strategy. The remaining 41 patients were treated with corticosteroids, either through dual steroid/SSI induction (n=19) or triple steroid/IVIG/SSI induction (n=22). A total of 4 patients failed the initial triple steroid/IVIG/SSI induction strategy, with all 41 patients achieving remission eventually. A corticosteroid-free SSI monotherapy maintenance strategy was successful in 73% of patients initially treated with corticosteroids.

Greater treatment delay predicted lower odds of successful maintenance with SSI monotherapy (odds ratio, 0.92; 95% CI, 0.85-0.97; P =.015). In patients with successful SSI monotherapy maintenance (n=23) vs those without (n=18), mean treatment delays were 1.7 months and 12.7 months, respectively (P =.048).

In addition, a significant percentage of patients presented with normal strength (n=22; 40%), suggesting that anti-HMGCR myopathy has diverse clinical presentations.

While corticosteroid-free induction was a safe option for select patients, initial induction with triple steroid/IVIG/SSI was highly efficacious in the treatment of anti-HMGCR myopathy. Success with SSI monotherapy appeared to favor early intervention. [A]voiding delays in treatment, most notably in patients with normal strength, may reset the natural history of anti-HMGCR myopathy from a refractory entity to a treatable disease, the investigators wrote.

Reference

Meyer A, Troyanov Y, Drouin J, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther. 2020;22(1):5.

Read the original:
Examining Treatment Options for Statin-Induced Anti-HMGCR Myopathy - Rheumatology Advisor

Rheumatoid Arthritis Therapeutics Industry 2020 Global Market Outlook To 2026

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 03/18/2020 -- Rheumatoid Arthritis Therapeutics Market Trends report provides detailed analysis and competitive analysis by region and other main information like a manufacturing process, raw material, and equipment suppliers, various manufacturing associated costs, historical & futuristic cost, revenue, demand and supply data, the actual process. Rheumatoid Arthritis Therapeutics report offers a detailed analysis of the industry, with market size forecasts covering the next four years. The Report contains complete coverage, intensive analysis, and actionable market insights to spot opportunities in existing and potential markets.

Market Analysis and Insights: Global Rheumatoid Arthritis Therapeutics Market. The global Rheumatoid Arthritis Therapeutics market, growing at a CAGR. Global Rheumatoid Arthritis Therapeutics Market: Drivers and Restrains The research report has incorporated the analysis of different factors that augment the market's growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones.

Get Sample Rheumatoid Arthritis Therapeutics Market Report

This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market expert's opinions have been taken to understand the market better.

The Global Rheumatoid Arthritis Therapeutics Industry 2020 Global Market research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Global Rheumatoid Arthritis Therapeutics market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The Global analysis is provided for the international markets including development Rheumatoid Arthritis Therapeutics market trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The report also focuses on global major leading industry players of Global Rheumatoid Arthritis Therapeutics market providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. The Global Rheumatoid Arthritis Therapeutics market development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

With tables and figures helping analyze worldwide Global Rheumatoid Arthritis Therapeutics market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The report also focuses on global major leading industry players of Global Rheumatoid Arthritis Therapeutics market providing information such as company profiles, product picture, and specification, capacity, production, price, cost, revenue and contact information. This report focuses on Rheumatoid Arthritis Therapeutics volume and value at a global level, regional level, and company level. From a global perspective, this report represents the overall Rheumatoid Arthritis Therapeutics market size by analyzing historical data and future prospects.

The Medical Transcription market has been created based on an in-depth market analysis with inputs from industry experts. The report covers the growth prospects over the coming years and discussion of the key vendors. The report provides a comprehensive analysis of key factors that are expected to drive the Medical Transcription Market growth.

About us:Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:

Fortune Business Insights Pvt. Ltd.

Supreme Headquarters,

Pune Banglore Highway, Baner, Pune,

Maharashtra 411045, India

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

For more information on this press release visit: http://www.sbwire.com/press-releases/rheumatoid-arthritis-therapeutics-market-2020-size-growth-forecast-to-2026-1282817.htm

Read the original:
Rheumatoid Arthritis Therapeutics Market 2020 Size, Growth Forecast to 2026 - Press Release - Digital Journal